Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) shares are trading higher Wednesday after the company announced that it was awarded a new patent covering AD04 for the potential treatment of opioid use disorder. The Details: Adial Pharmaceuticals said the patent was awarded by the United States Patent and Trademark Office on Feb. 20 and covers the company’s lead investigational new drug product, AD04, and its ability to target the serotonin transporter gene for the potential treatment of opioid use disorder. Benzinga broke the news first Wednesday morning with anexclusive report before the opening be…